PR Newswire
VIENNA, Nov. 6, 2017
VIENNA, Nov. 6, 2017 /PRNewswire/ -- (Booth X67) – West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it will, for the first time, showcase new extensions of its marketed SmartDose® drug delivery platform, including several new wearable injectors that allow for up to 10 mL of volume to be injected in easy-to-use, wearable formats. In addition, West will lead several educational sessions and presentations at the PDA Universe of Pre-filled Syringes and Injection Devices, taking place November 7-8, 2017 in Vienna, Austria, to address the pharmaceutical industry's top concerns regarding the containment and delivery of injectable medicines.
"Advancements in drug development need to be paired with advances in drug delivery, such as last year's FDA approval of the first combination product using our SmartDose drug delivery platform. Based on this technology, we are now excited to share our expanded portfolio of SmartDose wearable injectors," said Eric Resnick, Vice President and Chief Technology Officer at West. "As our customers continue to innovate and bring to market exciting new therapies to address important unmet medical needs, West is ready to help them with advancements in drug containment and delivery and technical expertise to guide them through the drug development and approval process."
West's SmartDose drug delivery platform allows patients to self-administer medication in accordance with their prescribed treatment. West developed this wearable device with extensive human factors testing and analysis to understand the interaction between the patient and the delivery system. All versions of the SmartDose platform adhere to the patient's body, usually on the abdomen, so patients can be hands free during administration. The SmartDose platform offers a variety of integrated solutions for delivery and containment featuring a silicone-free Daikyo Crystal Zenith® cartridge and a FluroTec® coated piston containment system. West has built upon the success of the Generation I (Gen. I) device to address market needs for higher-dose volumes and enhanced functionality and usability and now offers for development:
Both versions will be featured at the conference.
West will participate in the following educational sessions at the PDA Universe of Pre-filled Syringes and Injection Devices:
Tibor Hlobik, Sr. Director, Global Product Management, Prefilled Systems & Delivery at West, will lead a session on "Drug Delivery Systems: Global Technical, Regulatory and Quality Challenges": November 9, 3:30 p.m.
Additionally, West will present three scientific posters, which will be available in the Exhibit Hall during the conference:
For more information on West products and services, please visit booth X67 at PDA Universe of Pre-filled Syringes and Injection Devices or visit us online at www.westpharma.com.
Forward-Looking Statements
Certain forward-looking statements are included in this release. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West's SmartDose® drug delivery platform, or any other products, will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2016. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2016 net sales of $1.5 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
West and the diamond logo and FluroTec are trademarks or registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith and FluroTec technologies are licensed from Daikyo Seiko, Ltd.
NanoPass is a trademark of NanoPass Technologies Ltd.
Media Contact:
Emily Denney
Global Communications
West Pharmaceutical Services, Inc.
+ 1-610-594-3035
Emily.Denney@westpharma.com
View original content with multimedia:http://www.prnewswire.com/news-releases/west-to-showcase-new-extensions-of-the-smartdose-drug-delivery-platform-at-the-pda-universe-of-pre-filled-syringes-and-injection-devices-300549621.html
SOURCE West Pharmaceutical Services, Inc.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.